Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01436955 · ClinicalTrials.gov registry record · Phase 1

A Study of RG1662 in Individuals With Down Syndrome

A Phase 1 study of Down Syndrome, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
35
Enrollment target
9
Study locations

NCT01436955 is a Phase 1 study of Down Syndrome that has completed, run by Hoffmann-La Roche. The registered enrollment target is 35 participants, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01436955, a Phase 1 study of Down Syndrome, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
35 participants
Enrollment target
9
Study locations

Study Summary

This multi-center, randomized double-blind, placebo-controlled study will assess the safety and tolerability of RG1662 in individuals with Down Syndrome. Eligible subjects will be randomized in cohorts to receive either multiple oral doses of RG1662 or placebo. Anticipated time on study treatment is 38 days.

Conditions Studied

Down Syndrome

Interventions

  • DRUG Placebo
  • DRUG RG1662

Study Locations (9)

Arizona

  • - Phoenix

Arkansas

  • - Little Rock

California

  • - La Jolla

Colorado

  • - Aurora

Georgia

  • - Decatur

Illinois

  • - Chicago

Maryland

  • - Baltimore

North Carolina

  • - Durham

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2011-11
Est. Completion 2013-09
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01436955

The ClinicalTrials.gov registry entry for NCT01436955 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (99% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Down Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01436955 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arizona, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT01436955 about?

NCT01436955 is a clinical study titled "A Study of RG1662 in Individuals With Down Syndrome". This multi-center, randomized double-blind, placebo-controlled study will assess the safety and tolerability of RG1662 in individuals with Down Syndrome. Eligible subjects will be randomized in cohorts to receive either multiple oral doses of RG1662 or placebo. Anticipated time on study treatment is...

What is the current status of trial NCT01436955?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2011-11. Estimated completion is 2013-09.

What conditions does trial NCT01436955 study?

This clinical trial studies the following conditions: Down Syndrome.

What interventions are being tested in trial NCT01436955?

The interventions under investigation include: Placebo (DRUG), RG1662 (DRUG).

Who is sponsoring clinical trial NCT01436955?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01436955 being conducted?

This trial has 9 study locations across Arizona, Arkansas, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Down Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Down Syndrome

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.